Molecular Profiling Identifies Prognostic Subgroups of Pediatric Glioblastoma and Shows Increased YB-1 Expression in Tumors
Damien Faury(Montreal Children's Hospital), Nada Jabado(McGill University), André Nantel(Biotechnology Research Institute), László Bognár(Universität Hamburg), Takrima Haque(Montreal Neurological Institute and Hospital), Rolando F. Del Maestro(Artificial Intelligence in Medicine (Canada)), Torsten Pietsch(University Hospital Bonn), Miklós Garami(Media Working Group), Anne‐Sophie Carret(Montreal Neurological Institute and Hospital), Martin Gleave(University of British Columbia), Elvis Terci Valera(Society of Surgical Oncology), Sandra E. Dunn(Muscular Dystrophy UK), Enrique López‐Aguilar(Centro Medico Nacional Siglo XXI), Luíz Gonzaga Tone(Universidade de Ribeirão Preto), J.L. Martínez Montes(Montreal Neurological Institute and Hospital), Stephen Albrecht(Montreal Neurological Institute and Hospital), Marie-Christine Guiot(Montreal Neurological Institute and Hospital), Paweł P. Liberski(Medical University of Lodz), Zoltán Hanzély(Montreal Neurological Institute and Hospital), Péter Hauser(Buda Health Center)
Cited by 219
Related Papers
Intertumoral Heterogeneity within Medulloblastoma Subgroups
|Cancer Cell|2017|1.3k
K27M mutation in histone H3.3 defines clinically and biologically distinct subgroups of pediatric diffuse intrinsic pontine gliomas
|Acta Neuropathologica|2012|1k
Immune Checkpoint Inhibition for Hypermutant Glioblastoma Multiforme Resulting From Germline Biallelic Mismatch Repair Deficiency
|Journal of Clinical Oncology|2016|867